[go: up one dir, main page]

UY39304A - Métodos de administración segura de un oligonucleótido antisentido de irf5 - Google Patents

Métodos de administración segura de un oligonucleótido antisentido de irf5

Info

Publication number
UY39304A
UY39304A UY0001039304A UY39304A UY39304A UY 39304 A UY39304 A UY 39304A UY 0001039304 A UY0001039304 A UY 0001039304A UY 39304 A UY39304 A UY 39304A UY 39304 A UY39304 A UY 39304A
Authority
UY
Uruguay
Prior art keywords
irf5
methods
antisense oligonucleotide
safe administration
administration
Prior art date
Application number
UY0001039304A
Other languages
English (en)
Inventor
Damayahnthi Devineni
Bart Frederick
Cathye Shu
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of UY39304A publication Critical patent/UY39304A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los métodos para tratar a un sujeto humano que tiene una enfermedad asociada con el factor regulador de interferón 5 (IRF5) comprenden administrar al sujeto un oligómero antisentido a un ácido nucleico de IRF 5.
UY0001039304A 2020-07-01 2021-06-30 Métodos de administración segura de un oligonucleótido antisentido de irf5 UY39304A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063047169P 2020-07-01 2020-07-01
US202063047695P 2020-07-02 2020-07-02

Publications (1)

Publication Number Publication Date
UY39304A true UY39304A (es) 2021-12-31

Family

ID=76829594

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039304A UY39304A (es) 2020-07-01 2021-06-30 Métodos de administración segura de un oligonucleótido antisentido de irf5

Country Status (4)

Country Link
US (1) US20220002726A1 (es)
TW (1) TW202216171A (es)
UY (1) UY39304A (es)
WO (1) WO2022003595A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673616B1 (en) 1992-12-07 2004-01-06 Third Wave Technologies, Inc. Methods and compositions for characterizing nucleic acids
BR0009884A (pt) 1999-04-21 2002-01-08 American Home Prod Processos e composições para a inibição da função das sequências de polinucleotìdeos
US20140030218A1 (en) * 2011-01-05 2014-01-30 Imperial Innovations Limited Treatment And Screening
EP3118315A4 (en) * 2014-03-13 2017-11-15 Kyowa Hakko Kirin Co., Ltd. Nucleic acid that inhibits expression of irf5
US20180153922A1 (en) * 2016-12-06 2018-06-07 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease
US10420792B2 (en) * 2017-02-24 2019-09-24 The University of Pittsburgh—Of the Commonwealth System of Higher Education Method of treating severe asthma
EA202191342A1 (ru) * 2018-11-15 2021-08-10 Айонис Фармасьютикалз, Инк. Модуляторы экспрессии irf5

Also Published As

Publication number Publication date
TW202216171A (zh) 2022-05-01
WO2022003595A1 (en) 2022-01-06
US20220002726A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
CL2024000739A1 (es) Métodos para tratar fabry en pacientes con una mutación en el gen gla
MX2024003373A (es) Dosis de complejos dirigidos a musculos para el tratamiento de distrofinopatias.
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
ES2127203T3 (es) Vacunas y metodos para su produccion.
EA202191630A1 (ru) ХИМИЧЕСКИ МОДИФИЦИРОВАННЫЕ КОНСТРУКЦИИ ДЛЯ RNAi И ПУТИ ИХ ПРИМЕНЕНИЯ
AR097738A1 (es) Métodos para tratar o prevenir enfermedades asociadas con la transtiretina (ttr)
CL2020002352A1 (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
CL2021003280A1 (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal
AR114392A1 (es) Tratamiento de pacientes con enfermedad de fabry clásica
CO2021000914A2 (es) Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a
CL2021003474A1 (es) Producto farmacéutico para terapia enzimática para tratamiento de homocistinuria
MX2022002312A (es) Composicion farmaceutica para tratar cancer utilizada para un paciente que tiene un marcador genetico especifico.
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
CO6361950A2 (es) Composiciones, vacunas y metodos del virus del herpes del ganado bovino -1
ECSP13012524A (es) Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia
UY39304A (es) Métodos de administración segura de un oligonucleótido antisentido de irf5
AR119033A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
AR122819A1 (es) Métodos de administración segura de un oligonucleótido antisentido de irf5
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
AR095416A1 (es) Tratamiento con cutirsen que presenta una toxicidad reducida
AR120399A1 (es) Un método de tratamiento de un cáncer positivo para dll3
BR112022019357A2 (pt) Medicamento/agente para o tratamento de coronavírus, infecções retrovirais e hepatite c
AR122341A1 (es) Método para el tratamiento de cáncer utilizando célula adyuvante artificial (aavc)

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20241010